Mezzanzanica Delia (Delia Mezzanzanica)

Scopus Author ID Loop profile ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2018-2022
Publications (10 Years): 12

Top Topics

Metastatic Renal Cell Carcinoma

Diffusion Weighted

Patients Undergoing

Top Venues

Journal of experimental & clinical cancer research : CR

This page only lists publications with an associated author ORCID identifier.

Publications

Clorinda Schettino, Lucia Musacchio, Michele Bartoletti, Paolo Chiodini, Laura Arenare, Gustavo Baldassarre, Daniela Califano, Ettore Capoluongo, Maria Paola Costi, Maurizio D'Incalci, Sergio Marchini, Mezzanzanica Delia, Nicola Normanno, Stefania Scala, Stefano Greggi, Francesco Perrone, Sandro Pignata
Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 32 (6) (2022)
Marina Fabbi, Delfina Costa, Daniela Russo, Laura Arenare, Gabriele Gaggero, Simona Signoriello, Giovanni Scambia, Carmela Pisano, Nicoletta Colombo, Nunzia Simona Losito, Gilberto Filaci, Anna Spina, Daniela Califano, Giosuè Scognamiglio, Angiolo Gadducci, Mezzanzanica Delia, Marina Bagnoli, Silvano Ferrini, Vincenzo Canzonieri, Paolo Chiodini, Francesco Perrone, Sandro Pignata
Analysis of A Disintegrin and Metalloprotease 17 (ADAM17) Expression as a Prognostic Marker in Ovarian Cancer Patients Undergoing First-Line Treatment Plus Bevacizumab. Diagnostics (Basel, Switzerland) 12 (9) (2022)
Andrea Rizzo, Alessandro Satta, Giulia Garrone, Adalberto Cavalleri, Alessandra Napoli, Francesco Raspagliesi, Mariangela Figini, Loris De Cecco, Egidio Iorio, Antonella Tomassetti, Mezzanzanica Delia, Marina Bagnoli
Choline kinase alpha impairment overcomes TRAIL resistance in ovarian cancer cells. Journal of experimental & clinical cancer research : CR 40 (1) (2021)
Loris De Cecco, Marina Bagnoli, Paolo Chiodini, Sandro Pignata, Mezzanzanica Delia
Prognostic Evidence of the miRNA-Based Ovarian Cancer Signature MiROvaR in Independent Datasets. Cancers 13 (7) (2021)
Daniela Califano, Daniela Russo, Giosuè Scognamiglio, Nunzia Simona Losito, Anna Spina, Anna Maria Bello, Anna Capiluongo, Francesca Galdiero, Rossella De Cecio, Simona Bevilacqua, Piera Gargiulo, Edoardo Marchesi, Silvana Canevari, Francesco Perrone, Gennaro Daniele, Loris De Cecco, Mezzanzanica Delia, Sandro Pignata
Ovarian Cancer Translational Activity of the Multicenter Italian Trial in Ovarian Cancer (MITO) Group: Lessons Learned in 10 Years of Experience. Cells 9 (4) (2020)
Giorgio Bogani, Giovanni Apolone, Antonino Ditto, Giovanni Scambia, Pierluigi Benedetti Panici, Roberto Angioli, Sandro Pignata, Stefano Greggi, Paolo Scollo, Mezzanzanica Delia, Massimo Franchi, Fabio Martinelli, Mauro Signorelli, Salvatore Lopez, Violante Di Donato, Giorgio Valabrega, Gabriella Ferrandina, Innocenza Palaia, Alice Bergamini, Luca Bocciolone, Antonella Savarese, Fabio Ghezzi, Jvan Casarin, Ciro Pinelli, Vito Trojano, Vito Chiantera, Giorgio Giorda, Francesco Sopracordevole, Mario Malzoni, Giovanna Salerno, Enrico Sartori, Antonia Carla Testa, Gianfranco Zannoni, Fulvio Zullo, Enrico Vizza, Giuseppe Trojano, Antonio Chiantera, Francesco Raspagliesi
Impact of COVID-19 in gynecologic oncology: a Nationwide Italian Survey of the SIGO and MITO groups. Journal of gynecologic oncology 31 (6) (2020)
Frank Antony, Cecilia Deantonio, Diego Cotella, Maria Felicia Soluri, Olga Tarasiuk, Francesco Raspagliesi, Fulvio Adorni, Silvano Piazza, Yari Ciani, Claudio Santoro, Paolo Macor, Mezzanzanica Delia, Daniele Sblattero
High-throughput assessment of the antibody profile in ovarian cancer ascitic fluids. Oncoimmunology 8 (9) (2019)
Marina Bagnoli, Ting Yan Shi, Charlie Gourley, Paul Speiser, Alexander Reuss, Hans W Nijman, Carien L Creutzberg, Suzy Scholl, Anastassia Negrouk, Mark F Brady, Kosei Hasegawa, Katsutoshi Oda, Iain A McNeish, Elise C Kohn, Amit M Oza, Helen MacKay, David Millan, Katherine Bennett, Clare Scott, Mezzanzanica Delia
Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions. Cells 8 (3) (2019)
Francesca Roggiani, Cristina Riva, Francesco Raspagliesi, Giovanni Porta, Roberto Valli, Roberto Taramelli, Francesco Acquati, Mezzanzanica Delia, Antonella Tomassetti
A Cell-Autonomous Oncosuppressive Role of Human RNASET2 Affecting ECM-Mediated Oncogenic Signaling. Cancers 11 (2) (2019)
Alessandro Satta, Mezzanzanica Delia, Francesco Caroli, Barbara Frigerio, Massimo Di Nicola, Roland E Kontermann, Federico Iacovelli, Alessandro Desideri, Silvana Canevari, Alessandro Massimo Gianni
Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells. mAbs 10 (7) (2018)
Andrea Rizzo, Alessandra Napoli, Francesca Roggiani, Antonella Tomassetti, Marina Bagnoli, Mezzanzanica Delia
One-Carbon Metabolism: Biological Players in Epithelial Ovarian Cancer. International journal of molecular sciences 19 (7) (2018)
Rossella Canese, Gianmauro Palombelli, Mattea Chirico, Paola Sestili, Marina Bagnoli, Silvana Canevari, Mezzanzanica Delia, Egidio Iorio, Egidio Iorio
Integration of MRI and MRS approaches to monitor molecular imaging and metabolomic effects of trabectedin on a preclinical ovarian cancer model. NMR in biomedicine 32 (10) (2018)